USA flag logo/image

An Official Website of the United States Government

A novel vaccine: botulinum neurotoxin subunit on a viral carrier.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / STTR
Agency Tracking Number:
R42AI073064
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-124
Small Business Information
MOLECULAR TARGETING TECHNOLOGIES, INC.
833 LINCOLN AVE, UNIT 9 WEST CHESTER, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
Agency: HHS
Contract: 2R42AI073064-03A1
Award Amount: $2,509,160.00
 

Abstract:

DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, although there are major vaccine development initiatives ongoing, there currently is no approved Botulinum toxin vaccine available. Advances in Botulinum research have designated the optimal target for vaccine development to be the non-toxic carboxyterminal half of the toxin heavy chain (HC50). In fact, an immediate research goal for NIAID is listed as the development of a HC50 fragment vaccine against botulinum. Building upon the encouraging data from the phase I proof of concept study of this project,the overall phase II project goal is to develop a new, trivalent botulinum vaccine against the most common serotypes A, B and E. Three Aims are proposed for the further development of this novel trivalent BoNT vaccine as follows: Specific Aim 1: Vaccine vector construction and recovery. i) plasmid constructions, ii) demonstration of cell surface expression of the BoNT HC50, and iii) re-recovery of recombinant RVs from cDNA on Vero. Specific Aim 2. Vaccine vector characterization i) purification, inactivation, and in vitro characterization of the RV virions, ii) analysis of mouse immune responses to the vaccine using ELISA, in vitro neutralization assays, and in vivo protection of mice against a single challenge with BoNT or multiple BoNT challenge dependenton the used vaccine(s) for immunization. Specific Aim 3: Development of Pilot Production and Purification Processes. The overall goal of this aim is to translate the production process of our vaccine from a research setting to one suitable for pilot scalevaccine manufacture. PUBLIC HEALTH RELEVANCE: This research project is directly relevant to public health in that it is directed towards the development of a safe and effective vaccine for Botulinum neurotoxin. Botulinum toxin posesa major bioweapon threat because of its extreme potency andlethality and its ease of production and transport. A current investigational botulinum- toxoid vaccine requires multiple boosts to generate titers that are not very high, highlighting the need for an improved botulinum toxin vaccine. It is unclear if the current Botulinum vaccine protects at all as indicated by the disclaimer on the CDC vaccine consent form: ..., but other personal protective measures are still required. You should think of personal protectivemeasures as the only protective measure against any of these bacteria (sic) toxins at this time.

Principal Investigator:

Matthias J. Schnell
215-503-4634
matthias.schnell@jefferson.edu

Business Contact:

Koon Y. Pak
610-738-7938
cpak@mtarget.com
Small Business Information at Submission:

MOLECULAR TARGETING TECHNOLOGIES, INC.
833 LINCOLN AVE, UNIT 9 WEST CHESTER, PA -

EIN/Tax ID: 123310246
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
THOMAS JEFFERSON UNIVERSITY
THOMAS JEFFERSON UNIVERSITY
125 S 9th Street OFFICE OF RESEARCH ADMINISTRATION 2nd Floor Sheridan Building
PHILADELPHIA, PA 19107-5587
Contact: